Search

Author/Creator Ghermezi, Matthew

1. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Issue 5 (14th August 2022)

Authors:
Berenson, James R.; Kim, Clara; Bujarski, Sean; To, Jennifer; Spektor, Tanya M.; Martinez, Daisy; Turner, Carley; Ghermezi, Matthew; Eades, Benjamin M.; Swift, Regina A.; Schwartz, Gary; Eshaghian, Shahrooz; Moss, Robert A.; Lim, Stephen; Vescio, Robert
Journal:
Hematological oncology
Issue:
Volume 40:Issue 5(2022)
Page Start:
906
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. Issue 4 (21st March 2022)

Authors:
Yashar, David; Spektor, Tanya M.; Martinez, Daisy; Ghermezi, Matthew; Swift, Regina A.; Eades, Benjamin; Schwartz, Gary; Eshaghian, Shahrooz; Lim, Stephen; Vescio, Robert; Berenson, James R.
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 4(2022)
Page Start:
975
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. (June 2019)

Authors:
Chen, Haiming; Li, Mingjie; Xu, Ning; Ng, Nicole; Sanchez, Eric; Soof, Camilia M.; Patil, Saurabh; Udd, Kyle; Bujarski, Sean; Cao, Jasmin; Hekmati, Tara; Ghermezi, Matthew; Zhou, Mizi; Wang, Emily Y.; Tanenbaum, Edward J.; Zahab, Brian; Schlossberg, Remy; Yashar, Moryel A.; Wang, Cathy S.; Tang, ...
Journal:
Leukemia research
Issue:
Volume 81(2019)
Page Start:
62
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗